DEEP-IN-CELL Innovative single-cell RNA-seq kit to detect the rarer and more significant cellular genomic expressions

Summary

This project will develop and perform the industrial scale-up of a game-changing scRNA-seq tool named DEEP-IN-CELL. This solution, in a kit format plus a cloud software analysis suite, will use multiple barcode beads per cell to greatly improve the cell capture rate (over 80% versus 25-50% with current technologies) and the percentage of cell contents captured (2-3 times higher than the current levels of 10-20%). Proteomic profiles, specific genes, and cell types will also be targeted.
With high sensitivity to rare events, DEEP-IN-CELL will overcome the current limitations in single-cell research and expand the applications of scRNA-seq to important new clinical opportunities.
The product will reach the international single-cell research market and is expected to generate sales exceeding €100M by 2026. Scipio will become the uncontested provider of leading single-cell RNA-seq kits, thereby establishing a new standard and new best practices in single-cell research.

Resources Show all and search (0)

Unfold all

Fold all

More information & hyperlinks

Web resources:	https://cordis.europa.eu/project/id/190178154
Start date:	01-01-2023
End date:	31-12-2025
Total budget - Public funding:	3 453 227,50 Euro - 2 417 259,00 Euro

Cordis data

Original description

This project will develop and perform the industrial scale-up of a game-changing scRNA-seq tool named DEEP-IN-CELL. This solution, in a kit format plus a cloud software analysis suite, will use the proprietary hydrogel-based RevGel technology of Asteria kit as a basis for a new generation of kit that ambitions to dramatically simplify access to single-cell studies with a shorter time to result, far easier, robust and authentic transcriptome-preserving technology multiplied by reducing cost per sample. This new generation of kit shall bring a similar revolution to the single-cell market as did the Qiagen RNA extraction kit in its time to the genomic market, while providing performances at par with that of the market gold standard and monopolistic costive instrument-based single-cell technology 10xGenomics.
This next generation of single-cell RNAseq kit is expected to first launch in late 2024 with first applications to the international single-cell research market and to generate sales exceeding €50M by 2029. It is foreseen to become the quintessencial single-cell RNAseq kit that will open access to single-cell studies to a much broader research community.